KYVERNA THERAPEUTICS, INC.

Autres langues Kyverna Therapeutics, Inc.

Actions

KYTX

US5019761049

Temps Différé Nasdaq Autres places de cotation 21:55:15 04/06/2024			Varia. 5j.	Varia. 1 janv.
12,97 ^USD	-0,75 %		-2,19 %	0,00 %

14/05	Kyverna Therapeutics réduit sa perte au premier trimestre	MT
14/05	Kyverna Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kyverna Therapeutics Q1 Loss Narrows	14/05
Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	14/05
Nasdaq's revenue beats on strong demand for fintech products	25/04
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1	01/04
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med	29/03
Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results	26/03
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P TMI Index	18/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug	08/03
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03
Kyverna Therapeutics Closes $366.9 Million Initial Public Offering	13/02
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	12/02
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT